checkAd

     139  0 Kommentare AC Immune to Provide Strategy and Pipeline Update During Jefferies Virtual London Healthcare Conference - Seite 2

    For further information, please contact:

    Head of Investor Relations
    Joshua Drumm, Ph.D.
    AC Immune
    Phone: +1 917 809 0814
    Email: joshua.drumm@acimmune.com
    US Media
    Katie Gallagher
    LaVoie Health Science
    Phone: +1 617 792 3937
    Email: kgallagher@lavoiehealthscience.com
       
    Global Head of Communications
    Judith Moore
    AC Immune
    Phone: +41 79 826 63 82
    Email: judith.moore@acimmune.com
    European Investors & Media
    Chris Maggos
    LifeSci Advisors
    Phone: +41 79 367 6254
    Email: chris@lifesciadvisors.com

    Forward looking statements
    This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.


    Seite 2 von 2



    Diskutieren Sie über die enthaltenen Werte



    globenewswire
    0 Follower
    Autor folgen

    Weitere Artikel des Autors


    Verfasst von globenewswire
    AC Immune to Provide Strategy and Pipeline Update During Jefferies Virtual London Healthcare Conference - Seite 2 To feature discussion of the Company’s world-leading therapeutic and diagnostic candidates targeting TDP-43LAUSANNE, Switzerland, Nov. 12, 2020 (GLOBE NEWSWIRE) - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company …